An immunotherapy used against advanced non-small cell lung cancer is being tested at MD Anderson for a different job: preventing the disease from developing in people with pre-cancerous lung nodules.
The first-of-its-kind Phase II clinical trial is based on research into these precancerous growths by Jianjun Zhang, M.D., Ph.D., assistant professor of Thoracic/Head and Neck Medical Oncology.
How...
Researchers at The University of Texas MD Anderson Cancer Center have discovered important mechanisms of drug resistance and metastasis in...
Results from two MD Anderson studies demonstrated the significance of combination therapy in follicular lymphoma and chronic lymphoblastic...
MD Anderson’s adoptive cell therapy (ACT) platform is advancing the next generation of cell-based immune therapies to bring innovative approaches to our patients quickly, safely and effectively. The platform is one of the research engines driving MD Anderson’s Moon Shots Program®, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients’ lives.
By working closely...
November is Lung Cancer Awareness Month, and the third Thursday of each November is designated by the American Cancer Society as the Great...
Each year in the U.S., more than 50,000 people will be diagnosed with pancreatic cancer, which ranks around the 10th most common cancer type...
MD Anderson researchers have identified early genomic events that may lead to malignant transformation. They’ve found that tissue adjacent...
Combining two types of immune checkpoint inhibitor fires up responses in T cells that are separate from those initiated by the two drugs individually...
The recent outbreak of lung injury and death associated with e-cigarettes and vaping has led to a renewed scrutiny of electronic nicotine...
Despite major recent advances in oncology drug discovery, including the development of innovative targeted, immune and cell-based therapies...
Combining a 3D virtual cutting guide with a surgical navigation tool allowed MD Anderson surgeons to perform a complicated pelvic reconstruction...
Cancer’s ability to evolve in response to treatment and develop resistance to available therapies is one of the most significant challenges...
Despite the fact that the human papillomavirus (HPV) vaccine has been available in the U.S. for over 10 years and remains the only vaccine...
Glioblastoma (GBM) is not among the most commonly diagnosed cancers in the U.S., but it can certainly be among the most devastating. Of the...
Building upon the foundational discovery that the targeted therapy poziotinib is a potent and selective inhibitor of specific EGFR and HER2...
Results from two The University of Texas MD Anderson Cancer Center-led clinical trials indicate that targeted therapies led to significant...
Early results from two MD Anderson studies show promising responses to neoadjuvant (pre-surgical) checkpoint inhibitors in patients with advanced...
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer globally. Even with multimodality treatment, including surgery...
Repurposing FDA-approved therapies is a cost-effective way to bring new treatments to patients in need, but identifying those drugs with benefits...
MD Anderson researchers have developed the first machine learning algorithm to predict acute toxicities in patients receiving radiation therapy...
Multiple myeloma is the second most common hematological malignancy in the United States, and it’s increasing in incidence. An estimated 32,110...
A study from researchers at The University of Texas MD Anderson Cancer Center found that the prevalence of the types of oral human papillomavirus...
Small precancerous growths in the lungs are capable of progressing to invasive lung cancer, but so little has been known about them that understanding...
Even as women have gained ground in oncology, they remain under-represented as leaders of phase III clinical trials, MD Anderson researchers...
The addition of nivolumab to induction chemotherapy with idarubicin and cytarabine is feasible in patients with newly diagnosed acute myeloid...
According to the Centers for Disease Control and Prevention, the human papillomavirus is responsible for roughly 33,700 new cancer cases each...
A study at The University of Texas MD Anderson Cancer Center has shed information on a novel oncogenic pathway and points to the use of BET...
Prostate cancer is the most common cancer diagnosed in American men, and the second leading cause of cancer death in men. While hormone-based...
Using an antibody to plug a protein secreted by fibrous tissues in tumors stifles ovarian and pancreatic cancer in mouse models by reducing...
Just as a driver’s night vision improves by simply cleaning the headlights, scientists at The University of Texas MD Anderson Cancer Center...
An international consortium, led in part by clinicians and researchers from The University of Texas MD Anderson Cancer Center, has published...
A slice of RNA that doesn’t code for a protein manages to stifle tumor-suppressing genes and wreck the cellular mechanism that flags cancer...
Leukemia researchers at The University of Texas MD Anderson Cancer Center, working collaboratively with the Therapeutics Discovery division...
Combining two types of drugs that, separately, have extended the lives of people with metastatic melanoma has yielded higher response rates...
V. Craig Jordan, Ph.D., professor of Breast Medical Oncology, has been recognized for his “services to women’s health” with his appointment...
Improvements in breast cancer treatment over the past five decades have reduced the mortality rate of women with the disease by 40 percent...
MD Anderson researchers will present clinical trial results of promising combination therapies for a variety of cancers at the 2019 American...
Researchers at The University of Texas MD Anderson Cancer Center have shown how pretreatment clonal complexity in pancreatic tumor cells leads...
Researchers at MD Anderson Cancer Center have defined a new oncogene for B-cell lymphomas. The cancer-causing gene, known as heterogeneous...
Immunology research to investigate the mechanisms of a new aerosol treatment, which induces an innate immune response to protect against pathogens...
Nobel Laureate Jim Allison, Ph.D., invented immune checkpoint blockade immunotherapy by blocking the CTLA-4 protein on T cells, freeing those...
Testing for BRCA1 and BRCA2 seeks to identify mutations associated with increased risk of developing certain cancers over a person’s lifetime...
A randomized Phase III clinical trial combining two common chemotherapy agents as a pre-stem cell transplant treatment at The University of...
Unresectable pancreatic cancer is usually fatal because other treatments, such as radiation therapy, cannot be used. Radiation therapy causes...
Through in-depth retrospective analysis of data from more than 36,000 patients, a new study led by researchers at The University of Texas...
Whether it is new clinical trials for pediatric cancers or programs designed to increase access to smoking cessation programs for low-income...
Neoadjuvant therapy is treatment, such as chemotherapy or radiation, given before a patient has surgery. This approach is used in many cancer...
MD Anderson’s proteomics platform provides a valuable institutional resource, complete with state-of-the-art instruments and specialized expertise...
Chronic lymphocytic leukemia (CLL), which originates in white blood cells known as lymphocytes, is the most common form of leukemia in adults...
Glioblastoma is the most common, aggressive and deadly form of brain cancer. Median overall survival for primary glioblastoma is 14.6 months...
This is the second part of Cancer Frontline’s interview with Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology...
In October 2018, the Nobel Prize in Physiology or Medicine was awarded to Jim Allison, Ph.D., chair of Immunology, for his discoveries on...
MD Anderson Cancer Center researchers, together with collaborators from Mozambique, Brazil and the U.S., have been awarded a $5.1 million...
A Dream Team assembled by Stand Up To Cancer will receive $8 million in funding to research the use of modified immune cells to fight...
DNA damage response (DDR) inhibitors, such as poly (ADP-ribose) polymerase (PARP) inhibitors, are a type of targeted therapy used to treat...
Receiving a cancer diagnosis is a life-changing event, and the path through treatment can be among the hardest things a person goes through...
An innovative new technology is now providing radiation oncologists at MD Anderson Cancer Center a real-time view of tumors while they use...